Scholars Central

Conference abstractPublished 12 Sep 2011

Copro-antiapoptotic protein survivin and lactoferrin biomarkers for improved detection and nanodelivery to colon cancer

Authors: Jagat R Kanwar, Ganesh Mahidhara, Rupinder K Kanwar, Chun Hei Antonio Cheung

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

We and others have found that survivin, a member of the family of inhibitor of apoptosis proteins that is overexpressed in several human tumours. Lactoferrin is also known to express in infl ammatory diseases such as infl ammatory bowel disease and Crohn?s disease. We assessed the diff erential expression of survivin, other apoptotic biomarkers and lactoferrin in stool and serum samples of colorectal cancer (CRC) patients. We compared serum and stool samples from CRC patients and samples from healthy volunteers using an in vitro enzyme- linked immunosorbent assay to evaluate the survivin and lactoferrin response in patients. Th e sensitivity of the anti-survivin and lactoferrin response from patients with CRC was 65% and 70%, the specifi city was 62% and 75% respectively with good predictive positivity and predictive negativity. Combined detection using survivin and lactoferrin produced better sensitivity (65%) and specifi city (90%), respectively). In conclusion a positive association between survivin and lactoferrin concentrations in sera and stool samples of patients with CRCs was established. Our results suggest that analysis of both parameters would assist in screening patients with CRC. Our fi ndings also suggest that the reduction in the serum survivin and copro-lactoferrin levels of advanced CRC patients aft er chemotherapy can be used as a predictor of response to the chemotherapy but not that of survival. In addition, we developed dominant negative mutant of survivin (SurR9-C84A) and loaded into Alginate enclosed chitosan- calcium phosphate nano carriers (ACSC-NCs), in order to improve the oral bioavailability and to protect the peptide from the locale of gastro intestinal tract. Th ese CSC-NCs loaded with SurR9-C84A were tested in a xenograft mice model of colon cancer. We found all tumor bearing mice regressed tumors signifi cantly. Anti-tumor activity was mediated by inducing apoptosis and necrosis in tumours. Th ere was signifi cant decrease in angiogenesis and vasculature in the CSC NCs-SurR9-C84A as compared to empty CSC-NCs ingested control tumor mice. In the present study we developed a safe, nontoxic, mucoadhesive, completely biodeg radable, compatible and sustain released CSC- NCs as a proof of concept in colon cancer which can be used for other cancer types. Th us these CSC-NCs can be exploited for oral administration to protect from variable pH in intestinal track and resistance to gastric enzymes which othe rwise digest proteins in gastrointestinal tract

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Molecular Biomarkers & Diagnosis.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Molecular Biomarkers & Diagnosis
  • SubjectGenetics & Molecular Biology
  • SubjectPathology & Lab Medicine
  • BylineArticles whose byline prints “Jagat R Kanwar”
  • BylineArticles whose byline prints “Ganesh Mahidhara”
  • BylineArticles whose byline prints “Rupinder K Kanwar”
  • BylineArticles whose byline prints “Chun Hei Antonio Cheung”